JP2016512831A5 - - Google Patents

Download PDF

Info

Publication number: JP2016512831A5
Authority: JP; Japan
Prior art keywords: acceptable salt; pharmaceutically acceptable; same; compound; compound according
Prior art date: 2014-03-12
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP2016501574A

Other languages

English (en)

Japanese (ja)

Other versions

JP2016512831A (ja

Filing date

2014-03-12

Publication date

2017-10-12

2014-03-12 Application filed filed Critical

2014-03-12 Priority claimed from PCT/US2014/024564 external-priority patent/WO2014150925A2/en

2016-05-09 Publication of JP2016512831A publication Critical patent/JP2016512831A/ja

2017-10-12 Publication of JP2016512831A5 publication Critical patent/JP2016512831A5/ja

Status Pending legal-status Critical Current

Links

150000001875 compounds Chemical class 0.000 claims description 30
150000003839 salts Chemical class 0.000 claims description 17
201000010099 disease Diseases 0.000 claims description 12
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 10
239000003814 drug Substances 0.000 claims description 10
229910052739 hydrogen Inorganic materials 0.000 claims description 10
239000001257 hydrogen Substances 0.000 claims description 10
229940124597 therapeutic agent Drugs 0.000 claims description 10
YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 9
229910052805 deuterium Inorganic materials 0.000 claims description 9
206010028980 Neoplasm Diseases 0.000 claims description 7
239000008194 pharmaceutical composition Substances 0.000 claims description 6
206010006187 Breast cancer Diseases 0.000 claims description 4
208000026310 Breast neoplasm Diseases 0.000 claims description 4
206010009944 Colon cancer Diseases 0.000 claims description 4
208000001333 Colorectal Neoplasms Diseases 0.000 claims description 4
208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims description 4
208000034578 Multiple myelomas Diseases 0.000 claims description 4
206010035226 Plasma cell myeloma Diseases 0.000 claims description 4
125000000217 alkyl group Chemical group 0.000 claims description 4
125000003118 aryl group Chemical group 0.000 claims description 4
GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims description 4
229960001467 bortezomib Drugs 0.000 claims description 4
201000011510 cancer Diseases 0.000 claims description 4
125000002947 alkylene group Chemical group 0.000 claims description 3
230000000155 isotopic effect Effects 0.000 claims description 3
206010000830 Acute leukaemia Diseases 0.000 claims description 2
208000023275 Autoimmune disease Diseases 0.000 claims description 2
206010020751 Hypersensitivity Diseases 0.000 claims description 2
206010033128 Ovarian cancer Diseases 0.000 claims description 2
206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
229930012538 Paclitaxel Natural products 0.000 claims description 2
208000026935 allergic disease Diseases 0.000 claims description 2
230000007815 allergy Effects 0.000 claims description 2
229960002932 anastrozole Drugs 0.000 claims description 2
YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 claims description 2
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 2
229960003957 dexamethasone Drugs 0.000 claims description 2
239000003937 drug carrier Substances 0.000 claims description 2
208000005017 glioblastoma Diseases 0.000 claims description 2
206010073071 hepatocellular carcinoma Diseases 0.000 claims description 2
231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 2
229960003881 letrozole Drugs 0.000 claims description 2
HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 claims description 2
206010024627 liposarcoma Diseases 0.000 claims description 2
DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims description 2
229960001756 oxaliplatin Drugs 0.000 claims description 2
229960001592 paclitaxel Drugs 0.000 claims description 2
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 2
238000010348 incorporation Methods 0.000 claims 2
UFHFLCQGNIYNRP-VVKOMZTBSA-N Dideuterium Chemical compound [2H][2H] UFHFLCQGNIYNRP-VVKOMZTBSA-N 0.000 claims 1
206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
201000005202 lung cancer Diseases 0.000 claims 1
208000020816 lung neoplasm Diseases 0.000 claims 1
0 *C(*)(C(*)(*)C1(*)*)C(*)(*)C1(*)N(c(nc(Nc(cc1)ncc1N(C(*)(*)C(*)(*)N(*)C1(*)*)C1(*)*=C)nc1)c1C(*)=C1C(*)=O)C1=O Chemical compound *C(*)(C(*)(*)C1(*)*)C(*)(*)C1(*)N(c(nc(Nc(cc1)ncc1N(C(*)(*)C(*)(*)N(*)C1(*)*)C1(*)*=C)nc1)c1C(*)=C1C(*)=O)C1=O 0.000 description 1
101100005789 Caenorhabditis elegans cdk-4 gene Proteins 0.000 description 1
201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
230000000694 effects Effects 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
239000000203 mixture Substances 0.000 description 1
208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1

JP2016501574A 2013-03-15 2014-03-12 重水素化されたパルボシクリブ Pending JP2016512831A (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201361787540P	2013-03-15	2013-03-15
US61/787,540		2013-03-15
PCT/US2014/024564 WO2014150925A2 (en)	2013-03-15	2014-03-12	Deuterated palbociclib

Publications (2)

Publication Number	Publication Date
JP2016512831A JP2016512831A (ja)	2016-05-09
JP2016512831A5 true JP2016512831A5 (2)	2017-10-12

Family

ID=51581623

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2016501574A Pending JP2016512831A (ja)	2013-03-15	2014-03-12	重水素化されたパルボシクリブ

Country Status (8)

Country	Link
US (3)	US20160024084A1 (2)
EP (2)	EP2970209B1 (2)
JP (1)	JP2016512831A (2)
AU (1)	AU2014235462C1 (2)
CA (1)	CA2904054A1 (2)
EA (2)	EA201892726A1 (2)
MX (1)	MX2015012741A (2)
WO (1)	WO2014150925A2 (2)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR20170032244A (ko)	2014-07-26	2017-03-22	선샤인 레이크 파르마 컴퍼니 리미티드	Cdk 저해제로서 2-아미노-피리도[2,3-d]피리미딘-7(8h)-온 유도체 및 그 용도
CN105111201B (zh) *	2014-10-16	2017-01-11	上海页岩科技有限公司	5-甲基-2-(吡啶-2-基氨基)-8H-吡啶并[2,3-d]嘧啶-7-酮化合物
WO2016092442A1 (en) *	2014-12-08	2016-06-16	Sun Pharmaceutical Industries Limited	Processes for the preparation of crystalline forms of palbociclib acetate
CN104892604B (zh) *	2015-06-19	2016-08-24	北京康立生医药技术开发有限公司	一种cdk4抑制剂的合成方法
CN105153149B (zh) *	2015-07-29	2017-09-19	江苏中邦制药有限公司	一种选择性激酶抑制剂Palbociclib的制备方法
US11225492B2 (en) *	2015-12-13	2022-01-18	Hangzhou Innogate Pharma Co., Ltd.	Heterocycles useful as anti-cancer agents
CN106967064B (zh) *	2017-03-29	2018-03-23	郑州泰基鸿诺医药股份有限公司	氘代Palbociclib的衍生物、制备方法及其应用
CN106986871B (zh) *	2017-03-29	2019-02-26	浙江同源康医药股份有限公司	一种氘代Palbociclib的晶型及其制备方法和应用
BR112021001499A2 (pt)	2018-07-27	2021-04-27	California Institute Of Technology	inibidores de cdk e usos dos mesmos
CN113166148B (zh) *	2018-12-07	2024-04-12	杭州英创医药科技有限公司	作为cdk-hdac双通路抑制剂的杂环化合物
WO2021113595A1 (en) *	2019-12-06	2021-06-10	Beta Pharma, Inc.	Phosphorus derivatives as kras inhibitors
LV15575A (lv)	2019-12-20	2021-06-20	Latvijas Organiskās Sintēzes Institūts	Selenofēnhromēnu deiterēti analogi, to iegūšana un izmantošana

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5304121A (en)	1990-12-28	1994-04-19	Boston Scientific Corporation	Drug delivery system making use of a hydrogel polymer coating
US5886026A (en)	1993-07-19	1999-03-23	Angiotech Pharmaceuticals Inc.	Anti-angiogenic compositions and methods of use
US6099562A (en)	1996-06-13	2000-08-08	Schneider (Usa) Inc.	Drug coating with topcoat
TW354293B (en)	1995-06-06	1999-03-11	Bristol Myers Squibb Co	Prodrugs of paclitaxel derivatives
GB9925962D0 (en)	1999-11-02	1999-12-29	Novartis Ag	Organic compounds
HU229938B1 (en)	2001-05-03	2015-01-28	Hoffmann La Roche	Pharmaceutical dosage form of amorphous nelfinavir mesylate
CA2446904A1 (en)	2001-05-24	2003-04-03	Alexza Pharmaceuticals, Inc.	Delivery of drug esters through an inhalation route
ES2251677T3 (es)	2002-01-22	2006-05-01	Warner-Lambert Company Llc	2-(piridin-2-ilamino)-pirido(2,3-d)pirimidin-7-onas.
ATE412650T1 (de) *	2003-07-11	2008-11-15	Warner Lambert Co	Isethionat salz eines selektiven cdk4 inhibitors
US20060094744A1 (en)	2004-09-29	2006-05-04	Maryanoff Cynthia A	Pharmaceutical dosage forms of stable amorphous rapamycin like compounds
TW200819441A (en)	2005-10-28	2008-05-01	Abbott Lab	Prodrugs of compounds that inhibit TRPV1 receptor
BRPI0716880A2 (pt) *	2006-09-08	2013-10-15	Pfizer Prod Inc	Síntese de 2-(piridin-2-ilamino)-pirido[2,3-d]pirimidin-7-onas
CA2672898A1 (en)	2006-12-14	2008-06-26	Panacea Pharmaceuticals, Inc.	Methods of neuroprotection by cyclin-dependent kinase inhibition
US20090030005A1 (en)	2007-07-19	2009-01-29	Amgen Inc.	Combinations for the treatment of cancer
US9259399B2 (en)	2007-11-07	2016-02-16	Cornell University	Targeting CDK4 and CDK6 in cancer therapy
US7855204B2 (en) *	2008-01-22	2010-12-21	Concert Pharmaceuticals Inc.	Derivatives of gefitinib
JP2012504646A (ja)	2008-10-01	2012-02-23	ザユニバーシティオブノースカロライナアットチャペルヒル	選択的サイクリン依存性キナーゼ４／６阻害剤を用いた化学療法化合物に対する造血系の防護
CN102231983A (zh)	2008-10-01	2011-11-02	北卡罗来纳大学查珀尔希尔分校	使用选择性细胞周期蛋白依赖性激酶4/6抑制剂对抗电离辐射的造血防护
EP3406260B1 (en)	2009-05-13	2020-09-23	The University of North Carolina at Chapel Hill	Cyclin dependent kinase inhibitors and methods of use
UY33226A (es) *	2010-02-19	2011-09-30	Novartis Ag	Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6
WO2011130232A1 (en)	2010-04-13	2011-10-20	Novartis Ag	Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase (cdk4/6) inhibitor and an mtor inhibitor for treating cancer
CN101973989B (zh) *	2010-05-17	2012-07-18	苏州波锐生物医药科技有限公司	一种噻唑酰胺类化合物及其在治疗恶性肿瘤中的药物用途
EP2640394A4 (en)	2010-11-17	2015-02-25	Univ North Carolina	PROTECTION OF KIDNEY TISSUE FROM ISCHEMIA BY THE INHIBITION OF PROLEVERATIVE KINASES CDK4 AND CDK6

2014
- 2014-03-12 US US14/775,854 patent/US20160024084A1/en not_active Abandoned
- 2014-03-12 MX MX2015012741A patent/MX2015012741A/es unknown
- 2014-03-12 EA EA201892726A patent/EA201892726A1/ru unknown
- 2014-03-12 EA EA201591628A patent/EA032094B1/ru not_active IP Right Cessation
- 2014-03-12 CA CA2904054A patent/CA2904054A1/en not_active Abandoned
- 2014-03-12 AU AU2014235462A patent/AU2014235462C1/en not_active Ceased
- 2014-03-12 EP EP14769343.6A patent/EP2970209B1/en active Active
- 2014-03-12 JP JP2016501574A patent/JP2016512831A/ja active Pending
- 2014-03-12 EP EP18205631.7A patent/EP3492470A1/en not_active Withdrawn
- 2014-03-12 WO PCT/US2014/024564 patent/WO2014150925A2/en not_active Ceased
2017
- 2017-06-29 US US15/636,976 patent/US20180051022A1/en not_active Abandoned
2018
- 2018-11-13 US US16/189,304 patent/US20190225605A1/en not_active Abandoned

Publication	Publication Date	Title
JP2016512831A5 (2)	2017-10-12
JP2015508103A5 (2)	2016-03-10
JP2019529518A5 (2)	2020-10-22
JP2022017295A5 (2)	2022-07-04
JP2022017296A5 (2)	2022-06-13
JP2017524013A5 (2)	2017-10-05
JP2016501221A5 (2)	2017-01-12
JP2020007311A5 (2)	2020-09-03
JP2019507721A5 (2)	2020-01-16
JP2010531304A5 (2)	2011-07-28
JP2019510832A5 (2)	2020-05-14
JP2014510729A5 (2)	2015-04-23
JP2011515397A5 (2)	2012-05-10
JP2013522292A5 (2)	2014-04-03
JP2016523269A5 (2)	2017-08-10
JP2021522166A5 (2)	2022-03-24
RU2014115847A (ru)	2015-11-10	Пирролопиримидиновые соединения для лечения злокачественной опухоли
JP2019522055A5 (2)	2020-07-09
JP2016533366A5 (2)	2017-11-24
JP2018504441A5 (2)	2019-03-14
JP2019528307A5 (2)	2020-10-01
JP2015520143A5 (2)	2016-07-07
RU2015143542A (ru)	2017-04-19	Ингибиторы jak2 и alk2 и способы их использования
RU2015139901A (ru)	2017-03-24	Комбинированная терапия с использованием антител против клаудина 18.2 для лечения рака
JP2021514395A5 (2)	2022-03-01